1352435-37-0Relevant articles and documents
Synthesis and antitumor efficacy of a β-glucuronidase-responsive albumin-binding prodrug of doxorubicin
Legigan, Thibaut,Clarhaut, Jonathan,Renoux, Brigitte,Tranoy-Opalinski, Isabelle,Monvoisin, Arnaud,Berjeaud, Jean-Marc,Guilhot, Fran?ois,Papot, Sébastien
, p. 4516 - 4520 (2012/08/13)
In this paper we describe the synthesis and biological evaluation of the first β-glucuronidase-responsive albumin-binding prodrug designed for the selective delivery of doxorubicin at the tumor site. This prodrug leads to superior antitumor efficacy in mice compared to HMR 1826, a well-known glucuronide prodrug of doxorubicin that cannot bind covalently to circulating albumin. Furthermore, this compound inhibits tumor growth in a manner similar to that of doxorubicin while avoiding side effects induced by the free drug.